Association between the advanced glycosylation end product-specific receptor gene and cardiovascular death in older men by Biros, Erik et al.
RESEARCH ARTICLE
Association between the Advanced
Glycosylation End Product-Specific Receptor
Gene and Cardiovascular Death in Older Men
Erik Biros1, Corey S. Moran1, Paul E. Norman2, Graeme J. Hankey3,4, Bu B. Yeap3,5,
Osvaldo P. Almeida6,7,8, Leon Flicker3,7,9, RichardWhite10, Rhondda Jones1,
Jonathan Golledge1,11*
1 Queensland Research Centre for Peripheral Vascular Disease, College of Medicine and Dentistry, James
Cook University, Townsville, Australia, 2 School of Surgery, University of Western Australia, Perth, Australia,
3 School of Medicine and Pharmacology, University of Western Australia, Perth, Australia, 4 Department of
Neurology, Sir Charles Gairdner Hospital, Perth, Australia, 5 Department of Endocrinology, Fremantle and
Fiona Stanley Hospitals, Perth, Australia, 6 School of Psychiatry and Clinical Neurosciences, University of
Western Australia, Perth, Australia, 7 WACentre for Health and Ageing, Centre for Medical Research, Perth,
Australia, 8 Department of Psychiatry, Royal Perth Hospital, Perth, Australia, 9 Department of Geriatric
Medicine, Royal Perth Hospital, Perth, Australia, 10 Department of Neurology, The Townsville Hospital,
Townsville, Australia, 11 Department of Vascular and Endovascular Surgery, The Townsville Hospital,
Townsville, Australia
* jonathan.golledge@jcu.edu.au
Abstract
Advanced glycosylation end product-specific receptor (AGER) signaling has been impli-
cated in atherosclerosis. The aim of this study was to evaluate whether a common genetic
variation in the AGER gene is associated with cardiovascular (CV) death. We included 1304
older men who were genotyped for rs1035798:C>T, which is a single nucleotide polymor-
phism (SNP) mapped to the third intron of AGER. Cox proportional hazard analysis was
used to estimate the association of rs1035798:C>T with CV death. In addition we analyzed
total RNA extracted from carotid atherosclerosis biopsies of 18 patients that did or did not
have recent symptoms of cerebral embolization by quantitative real-time reverse transcrip-
tion PCR (qRT-PCR). The minor T-allele of rs1035798:C>T was found to be associated
with CV death under dominant (HR = 1.43, 95% CI: 1.01–2.02, P = 0.04) and recessive
(HR = 2.05, 95% CI: 1.11–3.81, P = 0.02) models of inheritance even after adjustment for
traditional cardiovascular risk factors. No association was found between rs1035798:C>T
and non-CV death. qRT-PCR results suggested that median relative expression of AGER
isoform 1 and isoform 6 transcripts were approximately 6- (P = 0.01) and 2-fold (P = 0.02)
greater, respectively, within carotid biopsies of symptomatic compared to asymptomatic
patients. These data suggest that the minor (T) allele of rs1035798:C>T represents an inde-
pendent susceptibility factor for CV death. The expression of AGER isoforms is different in
atheroma from patients with recent symptoms. Further studies are needed to investigate if
rs1035798:C>T influences the alternative splicing of AGER.
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Introduction
Cardiovascular disease (CVD) is the leading cause of mortality worldwide and thought to be
responsible for approximately 30% of deaths [1]. Most cardiovascular (CV) deaths are attrib-
uted to coronary heart disease (CHD) and stroke [2]. Acute rupture of an unstable atheroscle-
rotic plaque is thought to be an important cause of ischemic stroke and myocardial infarction
[3]. The exact mechanisms triggering plaque rupture are not completely clear, however mono-
cyte-derived macrophages are believed to play an important role [4–6]. Whereas classically
activated M1 macrophages are thought to promote inflammation [7], alternatively activated
M2 macrophages are believed to limit inflammation [8]. The M1 and M2 macrophages are
characterized by abundant production of inducible nitric oxide synthase (iNOS) and arginase 1
(ARG1), respectively, which makes these relatively specific markers for macrophage polariza-
tion in atherosclerosis [9].
A growing body of evidence suggests that advanced glycosylation end product-specific
receptor (AGER)-mediated cell signaling may be important in plaque stability [10–13]. AGER
is known to interact with a broad spectrum of ligands and multiple signaling pathways, such as
those activated by the high mobility group box 1 (HMGB1) protein (a non-canonical ligand of
AGER), important in the establishment of chronic inflammation [14]. Consistent with this
rs1035798:C>T, a non-coding single nucleotide polymorphism (SNP) in the AGER gene, has
been associated with clinically significant manifestations of atherosclerosis, such as ischemic
stroke [15]. Several splice variants encoding different isoforms, including full-length signaling
and truncated soluble variants, have previously been described for AGER [16]. The soluble
AGER isoforms are believed to be cytoprotective against excessive AGER signaling by acting as
decoy receptors [17]. In this paper, we provide evidence for the association of the AGER SNP
rs1035798:C>T with CV death and report differential expression of AGER isoforms within
biopsies of carotid atherosclerosis.
Materials and Methods
Participants
In order to assess the association of rs1035798:C>T with CV death we examined a group of
1304 community-dwelling men aged70 from the Health In Men Study (HIMS) who had
been prospectively followed for a mean of ~5.5 years through linked data. The characteristics
of HIMS participants have been described in details previously [18, 19]. The definitions of
CVD risk factors such as hypertension, dyslipidemia, diabetes, CHD, and smoking were also
previously described [20]. In brief, dyslipidemia, hypertension, and diabetes were defined by a
history of diagnosis or treatment of dyslipidemia, hypertension, or diabetes mellitus, respec-
tively. CHD was defined by a history of myocardial infarction, angina, or treatment for coro-
nary artery disease. Smoking was defined by history of ever-smoking. Waist-to-hip ratio
(WHR) was calculated from subjects’ waist and hip circumference that were measured in
accordance with guidelines of the International Society for the Advancement of Kinanthropo-
metry [21]. Participants were followed using the Western Australian Data Linkage System
(WADLS) which provides electronic linkage to data from the death registry and hospital mor-
bidity data system and has been shown to have excellent accuracy [22, 23]. Deaths due to car-
diovascular diseases were identified from the death registry using ICD-10 codes in the range
I00-I99 [24]. Carotid atheroma biopsies were collected in RNAlater solution (Ambion) from
18 patients undergoing carotid endarterectomy. Carotid artery atheromas were obtained from
11 subjects with recent symptoms of stroke or transient ischemic attack (TIA) and 7 asymp-
tomatic patients. Total RNA was extracted using RNeasy Mini Kit (Qiagen) according to
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manufacturer’s instructions. Ethical approval was granted from the University of Western Aus-
tralia and The Townsville Hospital and Health Services Committees and written informed con-
sent was obtained from each participant.
Genotyping
The human AGER is a highly polymorphic gene with more than 190 SNPs mapped to its locus
on the 6p21.3 chromosome [25]. A number of SNPs in AGER have previously been tested for
an association with a range of CVDs. However, most of these SNPs, including functional poly-
morphisms such as rs1800624, rs1800625, and rs2070600, have been reported to have no asso-
ciation with CVDs within a meta-analysis [26]. The rs1035798:C>T genetic variation, which is
a less-studied SNP in AGER and located at the genomic sequence position 5878 (g.5878C>T;
NG_029868.1), was selected for genotyping because of its relatively high level of heterozygosity
in white populations, thereby allowing the detection of all genotypes in a relatively small num-
ber of individuals [25]. In addition, the SNP has been previously associated with CVD,
although no functional significance of this intronic SNP has been established [15]. DNA of
HIMS subjects and patients undergoing carotid endarterectomy was extracted from total blood
samples collected in sodium citrate tubes using DNeasy Blood & Tissue Kit (Qiagen) according
to manufacturer’s instructions. Genomic DNA was supplied to the Australian Genome
Research Facility (AGRF Ltd, Australia) who performed genotyping of the HIMS subjects,
using the Sequenom’s MassARRAY system that utilizes a homogenous MassExtend (hME–sin-
gle base extension) reaction termed iPLEX GOLD. Genotype calls were made using SpectroTY-
PERTM RT software (Sequenom Inc., San Diego, CA, USA).
Tissue expression
We used total RNA samples obtained from 18 patients with and without recent symptoms of
cerebral embolization undergoing carotid endarterectomy. Four and 7 patients presented with
ischemic stroke and TIA, respectively, while 7 patients were asymptomatic. Quantitative real-
time reverse transcription PCR (qRT-PCR) was performed for two AGER isoforms, i.e. the
full-length variant (isoform 1 or AGER) that represents the predominant AGER transcript and
the truncated splice variant (isoform 6 or esAGER) that is the primary secreted isoform of
AGER [27]. In addition, we assessed the expression of high-mobility group box 1 (HMGB1), a
gene coding for a non-canonical AGER ligand (considered to be an important biological
marker of inflammation [28]) and the arginase 1 (ARG1) gene, that is abundantly produced by
M2 macrophages [29] (which are thought to play an important role in atherosclerotic plaque
stability [5, 30]). The relative expression of selected genes in each sample was calculated by
using the concentration-Ct-standard curve method and normalized using the average expres-
sion of the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene for each sample using
the Rotor-Gene Q operating software version 2.0.24 (Qiagen). GAPDH was chosen as the
“housekeeping” gene since analyses showed its expression to be similar in carotid biopsies
from symptomatic and asymptomatic patients. The QuantiTect SYBR Green one-step RT-PCR
Kit (Qiagen) was used according to the manufacturer’s instructions with 20 ng of total RNA as
template. All reactions were independently repeated in duplicate to assess the repeatability of
the results and the mean of the two values for each sample was used for analyses. SYBR Green
qPCR primers were designed using the AlleleID software (PREMIER Biosoft) for AGER iso-
form 1 (5’-GGTCATCTTGTGGCAAAG-3’ and 5’-CTCTTCCTCCTGGTTTTC-3’, reference
sequence NM_001136), and AGER isoform 6 (5’-TCAGCATCAGCATCATCG-3’ and 5’-
TTCTGCTTCCCTGACTTTATC-3’, reference sequence NM_001206940). QuantiTect Primer
Assays (Qiagen) QT01002190, QT00068446, and QT00079247 were used for theHMGB1,
AGER and Cardiovascular Morbidity
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ARG1, and GAPDH assessments, respectively. Mann–Whitney U test was performed to iden-
tify differences in expression levels of the selected transcripts between patients presenting with
symptomatic and asymptomatic carotid artery disease. All computations were performed using
the SPSS statistical package v.17.0.2. Statistical significance was defined at the conventional 5%
level.
In silico analysis of rs1035798:C>T
The rs1035798:C>T SNP is located in the third intron of the AGER gene (MIM 600214). Func-
tional in silico analysis of this non-coding SNP was performed using the Function Analysis and
Selection Tool for Single Nucleotide Polymorphism (FASTSNP) server and the Human Splic-
ing Finder (HSF) v2.4.1 tool to identify the most likely functional effects of rs1035798:C>T on
AGER [31, 32]. FASTSNP evaluates putative functional effects of SNPs, including changes to
the transcriptional level and pre-mRNA splicing. A FASTSNP risk score of very high, moderate
to high or low to moderate is assigned to the most likely functional effects. The HSF tool is
designed to identify putative donor and acceptor splice sites, branch points (BPs), and cis-act-
ing elements such as exonic splicing enhancer (ESE) and exonic splicing silencer (ESS).
Statistical analysis of the genotype data
For the genotype analysis the outcome of interest was the occurrence of CV death. Cox regres-
sion analysis was used to model the association between rs1035798:C>T genotypes and multi-
ple covariates with CV death under dominant, recessive, and additive models of inheritance.
Our data set contained no missing values. Results are presented as hazard ratios (HR) and 95%
confidence intervals (95% CI). Selection of covariates was based on clinical significance as
described previously [33]. A dominant model measured differences between T-allele carriers
and C/C homozygotes of rs1035798:C>T, while a recessive model compared T/T homozygotes
with C-allele carriers of rs1035798:C>T. An additive model imposed a genetic structure in
which each additional copy of the rs1035798:C>T minor (T) allele increased HR by the same
amount. Hardy-Weinberg equilibrium was tested using HPlus v3.1 [34]. Cox analysis was per-
formed using the SPSS Statistics 22. The date of birth and of last follow-up was used to define
survival time and those participants that did not die were censored at the date of last data link-
age. A similar analysis was performed to assess the association of rs1035798:C>T with non-
CV death. Statistical significance was defined at the conventional 5% level. The available sam-
ple sizes had>80% power to detect the effect size (HR) of approximately 1.4 for the association
of rs1035798:C>T genotypes with CV death. Power calculations were performed by using the
PS: Power and Sample Size Calculation v3.0 software [35]. Finally, Kaplan-Meier curves were
constructed to estimate the probability of CV and non-CV death in relation to rs1035798:C>T
genotypes and compared using the Mantel-Cox log-rank test. For all analysis assessing this
SNP as a risk factor for mortality the time from birth to death or data censorship was used.
Results
Participant characteristics
Genotyping was carried out in 1304 HIMS men. Baseline characteristics of HIMS subjects are
shown in Table 1. Participants had a frequent history of ever smoking (882/1304, 68%), hyper-
tension (554/1304, 42%) and dyslipidemia (483/1304, 37%). Over a mean follow-up period of
5.51±1.57 years 484 deaths occurred, of which 131 (27%) were due to fatal cardiovascular
events (Table 1).
AGER and Cardiovascular Morbidity
PLOS ONE | DOI:10.1371/journal.pone.0134475 July 30, 2015 4 / 12
Cox proportional hazard analysis
The frequency of the rs1035798:C>T minor (T) allele was 0.21 (Table 2). The genotype distri-
bution of rs1035798:C>T passed testing for Hardy-Weinberg equilibrium in HIMS men
(P = 0.12; Table 2) and was therefore assessed for association with CV death. Multivariate anal-
ysis showed that the rs1035798:C>T minor (T) allele was significantly associated with CV
death under dominant (HR = 1.43, 95% CI: 1.01–2.02, P = 0.04) and recessive (HR = 2.05, 95%
CI: 1.11–3.81, P = 0.02) models of inheritance after adjustment for traditional CVD risk factors
Table 1. Characteristics of subjects included in this study.
Characteristic HIMS group Gene expression group
Symptomatic Asymptomatic P
Number 1304 11 7 -
Males 1304 (100%) 9 (82%) 5 (71%) 0.65
Age (years) 72.64±4.06 69.16±9.45 72.45±6.19 0.54
Follow-up (years) 5.51±1.57 - - -
Total deaths 484 (37%) 0 (0%) 0 (0%) -
CV deaths 131 (10%) - - -
Age at CV death 82.65±4.59 - - -
Waist-to-hip ratio 0.96±0.06 1.00±0.24 0.91±0.11 0.64
Diabetes 106 (8%) 2 (18%) 2 (29%) 0.65
Hypertension 554 (42%) 8 (73%) 6 (86%) 0.59
Past stroke 80 (6%) 4 (36%) 0 (0%) -
Transient ischaemic attack N/A 7 (64%) 0 (0%) -
Coronary heart disease 325 (25%) 3 (27%) 4 (57%) 0.26
Dyslipidemia 483 (37%) 7 (64%) 5 (71%) 0.77
Ever smoking 882 (68%) 11 (100%) 5 (71%) 0.14
Age, calendar age at entry-to-study; HIMS, Health In Men Study; P, two-sided P value; N/A, not available; (-), not applicable. Nominal variables are
presented as numbers, while continuous variables are presented as mean ± standard deviation (SD). Nominal and continuous variables were compared
between subjects in the gene expression study using Fisher’s exact test and Mann-Whitney U test, respectively.
doi:10.1371/journal.pone.0134475.t001
Table 2. Association of rs1035798:C>T with death in HIMS subjects.
Inheritance Genotype N (%) MAF HWE CV death Non-CV death
HR 95% CI P HR 95% CI P
Additive C/C 830 (63.6) 0.21 0.12 - - - - - -
T/C 409 (31.4) 1.32 0.91–1.90 0.15 1.01 0.80–1.27 0.94
T/T 65 (5.0) 2.27 1.20–4.28 0.01 0.97 0.57–1.67 0.92
Dominant C/C 830 (63.6) 0.21 0.12 - - - - - -
T/C 409 (31.4) 1.43 1.01–2.02 0.04 1.00 0.81–1.25 0.97
T/T 65 (5.0)
Recessive C/C 830 (63.6) 0.21 0.12 - - - - - -
T/C 409 (31.4)
T/T 65 (5.0) 2.05 1.11–3.81 0.02 0.97 0.57–1.66 0.91
N, number of individuals; MAF, observed minor allele frequency; HWE, Hardy-Weinberg equilibrium chi-squared test P value; HR, hazard ratio; 95% CI,
95% confidence interval. Adjusted for CHD, diabetes, dyslipidemia, hypertension, smoking, and WHR.
doi:10.1371/journal.pone.0134475.t002
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(Table 2). Analysis was adjusted for CHD, diabetes, dyslipidemia, hypertension, ever smoking,
and WHR. To assess if rs1035798:C>T was specifically associated with CV death as opposed
to other causes of death, an additional analysis was performed to investigate the association of
rs1035798:C>T with non-CV death. No association was detected (Table 2).
Kaplan Meier-Analysis
The association of rs1035798:C>T with CV death was further examined using Kaplan-Meier
analysis. The results are shown in Fig 1. An increased probability of CV death in relation to
rs1035798:C>T minor (T) allele was seen under a dominant (P = 0.04; Fig 1A) and recessive
(P = 0.03; Fig 1B) model of inheritance. The minor T-allele of rs1035798:C>T had no associa-
tion with the probability of non-CV death (P>0.05; Fig 1C and 1D).
Gene expression analysis
A gene expression analysis was performed using carotid atheroma biopsies obtained from a
group of 18 subjects comprised of 11 and 7 patients with and without recent symptoms of cere-
bral embolization, respectively (Table 1). Symptomatic patients presented with TIA (N = 7)
Fig 1. Kaplan-Meier analysis illustrating probability of death in relation to AGER rs1035798:C>T genotypes. The minor (T) allele of rs1035798:C>T
was associated with an increased probability of CV death under a dominant (A; P = 0.04) and recessive (B; P = 0.03) model of inheritance. The T-allele had
no association with the probability of non-CV death under a dominant (C; P = 0.95) and recessive (D; P = 0.87) model of inheritance.
doi:10.1371/journal.pone.0134475.g001
AGER and Cardiovascular Morbidity
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and ischemic stroke (N = 4). Symptomatic and asymptomatic patients were similar in all of
their baseline characteristics (Table 1). Median relative expression of AGER isoform 1 and iso-
form 6 transcripts were approximately 6- (P = 0.01) and 2-fold (P = 0.02) greater, respectively,
within carotid biopsies of symptomatic compared to asymptomatic patients (Fig 2). Addition-
ally, we assessed the expression of theHMGB1 gene and found that median relative expression
ofHMGB1 transcript was ~3-fold upregulated within carotid biopsies of symptomatic com-
pared to asymptomatic patients (P = 0.02; Fig 3A). Finally, median relative expression of the
ARG1 transcript was similar within carotid biopsies of symptomatic and asymptomatic
patients (P = 0.82; Fig 3B).
Fig 2. Differential expression of AGER isoforms in carotid atheroma biopsies from patients with and without symptoms of cerebral embolization.
Expression of AGER isoform 1 (A; **P = 0.01) and AGER isoform 6 (B; *P = 0.02) was more than 6- and 2-fold greater within carotid atheroma biopsies of
symptomatic compared to asymptomatic patients. Data expressed as median and interquartile range with maximum and minimum data points (whiskers) for
relative expression.
doi:10.1371/journal.pone.0134475.g002
Fig 3. Differential expression of HMGB1 and ARG1 in carotid atheroma biopsies of patients with and without symptoms of cerebral embolization.
Increased expression of HMGB1 (A; *P = 0.02) but not ARG1 (B; P = 0.82) within carotid atheroma biopsies of symptomatic compared to asymptomatic
patients. Data expressed as median and interquartile range with maximum and minimum data points (whiskers) for relative expression.
doi:10.1371/journal.pone.0134475.g003
AGER and Cardiovascular Morbidity
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In silico analysis of rs1035798:C>T
The in silico assessment of rs1035798:C>T was performed by using the FASTSNP and HSF
bioinformatics tools. The rs1035798:C>T SNP was predicted to affect a splicing site with a
moderate to high risk score by the FASTSNP software. Similarly, the HSF tool predicted that
the rs1035798:C>Tminor (T) allele breaks the recognition site for serine/arginine-rich splicing
factor 5 (SRSF5) that is a member of the serine/arginine (SR)-rich family of pre-mRNA splicing
factors.
Discussion
We report an association between the AGER SNP rs1035798:C>T and CV death in older men.
There was no association between this SNP and non-CV death. These findings are compatible
with previous work on other inflammatory conditions such as multiple sclerosis (MS) assessed
in white and African American MS cases and controls [36]. Although CVD and MS represent
clinically distinct conditions, the association of rs1035798:C>T with these diseases would
appear to be consistent across the different ethnic groups studied despite different allele fre-
quencies. The frequency of rs1035798:C>T minor (T) allele is approximately 2% and 20% in
African American and white populations, respectively [25]. AGER is a transmembrane signal
transduction receptor with a number of ligands, including alarmins that can initiate and per-
petuate immune responses [37]. AGER naturally exists in two forms that are full-length mem-
brane-bound and truncated (soluble) [38]. The soluble form of AGER consists of several
variants of different origin, including the endogenous secretory AGER (esAGER), which is a
splice variant of the AGER gene transcript [38]. The esAGER protein contains all extracellular
domains but not membrane and intracellular domains of the full-length AGER which preserves
binding but not signaling capabilities [39]. We assessed the expression of AGER isoform 1 that
codes for the full-length AGER protein and its splice variant AGER isoform 6, encoding the
truncated esAGER protein, in samples of carotid atherosclerosis removed from patients under-
going carotid endarterectomy. Our findings that AGER isoform 1, and to a lesser extend AGER
isoform 6 are upregulated within biopsies obtained from patients with symptoms compared to
those without symptoms are in line with previous findings suggesting that AGER signaling is
upregulated within vulnerable regions of atherosclerotic plaques [40]. The protein product of
isoform 6 (esAGER) is believed to be protective against excessive AGER signaling [17], suggest-
ing a role of this isoform in maintaining plaque stability. It has been proposed that alternative
splicing of genes may correlate with sequence variations such as SNPs [41]. Our in silico analy-
sis of rs1035798:C>T, an intronic SNP of AGER, predicted that the minor (T) allele of this
SNP is expected to disrupt a recognition site for splicing factors that are involved in constitu-
tive and alternative pre-mRNA splicing. It is possible that rs1035798:C>T influences the bal-
ance between AGER isoforms in atherosclerosis, however, this study does not identify a clear
mechanism by which this SNP is associated with fatal CV events. The expression of AGER iso-
forms was not assessed in relation to rs1035798:C>T genotypes due to small number of carotid
biopsies available.
Previous evidence suggests that complications of atherosclerosis result in part from the pro-
teolytic activity of infiltrating inflammatory cells, notably macrophages, which promotes thin-
ning of the fibrous cap and plaque rupture [5, 30]. In line with this, our current findings
suggest marked upregulation of HMGB1, a gene coding for the non-canonical ligand of AGER,
in patients with symptoms of carotid embolization. HMGB1 belongs to the group of endoge-
nous damage-associated molecular pattern molecules (DAMPs), also known as alarmins.
HMGB1 is passively released from necrotic cells and actively secreted from activated immuno-
competent cells, including macrophages [42]. Extracellular HMGB1 has, however, inhibitory
AGER and Cardiovascular Morbidity
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effects on phagocytic activity of macrophages (efferocytosis) that is critical to the resolution of
inflammation [43, 44]. Consistent with this, Shaikh and co-workers showed by their compre-
hensive immunohistochemical assessments that unstable carotid plaques are characterized by a
predominance of M1-like pro-inflammatory macrophages and a decreased proportion of
atheroprotective M2-cells compared to femoral atheroma in humans [45]. Femoral atheroma
has been suggested to be more typically associated with the stable flow-limiting symptoms
rather than acute thromboembolism [46]. We found no evidence to support the association of
M2 cells and carotid atheroma phenotype. We found similar expression of ARG1, a gene abun-
dantly expressed by M2-macrophages [29], in patients that did and did not have symptoms of
carotid embolization. In this context, previous evidence suggests marked upregulation of iNOS
within unstable compared to stable human carotid plaques [47]. iNOS is abundantly produced
by M1 macrophages, and importantly, this enzyme competes with ARG1 for the common sub-
strate, L-arginine [48]. These and the current results collectively suggest an increase in the M1/
M2 macrophage ratio in unstable atheroma and the possibility that L-arginine could have a
plaque stabilizing effect. Possible pharmacological intervention may include cationic poly-
amines, such as poly-L-arginine, that can block the cellular uptake of L-arginine [49]. This,
however, needs examining in other contexts, e.g. translational animal models that produce vul-
nerable plaques [50]. Currently there are no diagnostic or prognostic blood markers that can
reliably identify patients developing ischemic complications of atherosclerosis. Our findings
warrant further investigation with possible implications for the clinical management of athero-
sclerotic disease. Measuring circulating levels of AGER and HMGB1 may provide a useful clin-
ical aid, the potential for which needs to be investigated.
The current study has a number of limitations. In order to assess the association of
rs1035798:C>T with CV death, we included approximately 1300 participants prospectively
followed over a mean period of ~5 years. Although CV death accounted for approximately 1 of
every 4 deaths recorded in this study, the absolute number of 131 fatal CV events was relatively
small, though sufficiently large to estimate statistically significant effect sizes. This, however,
needs to be substantiated by larger studies and those involving different ethnicities. Detailed
imaging of coronary, carotid, and cerebrovascular arteries was not performed. Additionally, all
HIMS participants were men of largely white ethnicity limiting the relevance of our finding to
women or other ethnicities. Recruitment of HIMS subjects focused on older men and thus our
study is subject to healthy bias. It is therefore possible that the effect of rs1035798:C>T could
be different if assessed in a cohort recruited at a younger age. Furthermore, we were only able
to obtain proximal internal carotid artery biopsies taken from patients with and without recent
symptoms of cerebral embolization for our gene expression study. The additional use of alter-
native samples such as coronary artery biopsies from patients undergoing coronary artery
bypass grafting would have been useful to ensure the generalizability of our findings. Finally,
the number of carotid artery plaque biopsies available for our gene expression study was lim-
ited which did not allow us to assess the differential expression of selected genes and isoforms
in relation to rs1035798:C>T genotypes. Larger studies are required to assess this in detail.
Conclusion
In conclusion, the current study suggests that rs1035798:C>T is associated with CV death. The
finding needs validation in other cohorts.
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